Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CatalYm

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
From CatalYm
Via Business Wire
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
From CatalYm
Via Business Wire
CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO
From CatalYm
Via Business Wire
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
From CatalYm
Via Business Wire
CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature
From CatalYm
Via Business Wire
CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference
From CatalYm
Via Business Wire
CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
From CatalYm
Via Business Wire
CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting
From CatalYm
Via Business Wire
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists
From CatalYm
Via Business Wire
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
From CatalYm
Via Business Wire
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
From CatalYm
Via Business Wire
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
From CatalYm
Via Business Wire
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
From CatalYm
Via Business Wire
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023
From CatalYm
Via Business Wire
CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting
From CatalYm
Via Business Wire
CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort
From CatalYm
Via Business Wire
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
From CatalYm
Via Business Wire
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U.S.
From CatalYm
Via Business Wire
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress
From CatalYm
Via Business Wire
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
From CatalYm
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.